Figure 5.

PpM1 treatment enhanced T cells infiltration and remolded the tumor immune microenvironment

Tumors (n = 6) were harvested on day 16 and stained for an array of immune cell markers before being analyzed by flow cytometry.

(A) The schedule of the experiment.

(B and C) Tumor volume (B) and body weight of mice (C) on day 16 after tumor inoculation.

(D–H) Immune profiling in MC38 tumor with or with ppM1 treatment, showing CD45⁺ leukocytes (D), CD3⁺ T lymphocytes (E), CD8⁺ T cells (F), IFN-γ⁺ cytotoxic T cells (G), and CD4⁺ T cells (H). Each dot represents data for one mouse and error bars represent SDs. (C–H) was analyzed with two-tailed unpaired t test; ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001 (See also Figure S8).